The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Tyrosine kinase inhibitors.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Tyrosine kinase inhibitors is a key innovation area in pharmaceutical drug development

Tyrosine kinases catalyse the phosphorylation of select tyrosine residues in target proteins by using adenosine triphosphate (ATP). They can be divided into receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases (NRTKs), and a few dual-specificity kinases (DSKs), which can phosphorylate serine, threonine, and tyrosine residues. Tyrosine kinase inhibitors (TKIs) are a group of drugs that interfere with the signal transduction pathways of protein kinases, compete with ATP for the ATP binding site of PTK, and reduce tyrosine kinase phosphorylation, thereby inhibiting the proliferation of cancer cells.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of tyrosine kinase inhibitors.

Key players in tyrosine kinase inhibitors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to tyrosine kinase inhibitors

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Seattle Children's Hospital 61 Unlock company profile
F. Hoffmann-La Roche 60 Unlock company profile
Cell Signaling Technology 55 Unlock company profile
Arog Pharmaceuticals 51 Unlock company profile
Opthea 42 Unlock company profile
Celldex Therapeutics 40 Unlock company profile
NMS Group 38 Unlock company profile
Pfizer 36 Unlock company profile
A. Menarini Industrie Farmaceutiche Riunite 35 Unlock company profile
City of Hope 34 Unlock company profile
OncoPlex Diagnostics 28 Unlock company profile
Aravive 23 Unlock company profile
Ligacept 22 Unlock company profile
UK Research and Innovation 21 Unlock company profile
Debiopharm Group 19 Unlock company profile
Bristol-Myers Squibb 17 Unlock company profile
National Cancer Center 17 Unlock company profile
LifeSci Index Partners 14 Unlock company profile
Precigen 13 Unlock company profile
UAB Research Foundation 13 Unlock company profile
C. H. Boehringer Sohn 12 Unlock company profile
Sumitomo Chemical 11 Unlock company profile
Denka 10 Unlock company profile
Catalent 10 Unlock company profile
Genemedicine 9 Unlock company profile
WellMarker Bio 8 Unlock company profile
Vaxon Biotech 8 Unlock company profile
Shenzhen Salubris Pharmaceuticals 7 Unlock company profile
Calitor Sciences 6 Unlock company profile
Autolus 5 Unlock company profile
Memorial Sloan Kettering Cancer Center 5 Unlock company profile
Amgen 5 Unlock company profile
Assistance Publique - Hopitaux de Paris 5 Unlock company profile
Centre National de la Recherche Scientifique 5 Unlock company profile
HEC Pharm Group 5 Unlock company profile
Vegenics 5 Unlock company profile
Cell Medica Switzerland 5 Unlock company profile

Source: GlobalData Patent Analytics

Seattle Children's Hospital is the leading patent filer in tyrosine kinase inhibitors. Seattle Children's Hospital is a healthcare centre that offers paediatric and adolescent services. The centre conducts paediatric research and provides patient care services. It has operations in Seattle, Everett, Bothell, Wenatchee, Richland and Federal Way.

F. Hoffmann-La Roche and Arog Pharmaceuticals are the other key patent filers in the tyrosine kinase inhibitors space.

In terms of application diversity, Precigen is the top company, followed by F. Hoffmann-La Roche and Debiopharm Group. By means of geographic reach, Seattle Children's Hospital holds the top position. Whilst Celldex Therapeutics and UAB Research Foundation stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.